WDR5 and cancer: The primary aim of the researcher is to design PROTAC to induce selective degradation of WDR5 using OICR-9429, a low-molecular substance capable of pharmacologically targeting WDR5, hence confirming whether the proliferation of cancer cells is inhibited by destroying the KMT2 complex in cancer cells.